The Bengaluru-based company makes CAR-T therapy, a form of cancer treatment where a patient’s own immune cells are taken out, trained in a ...

Executives from the technology, semiconductor and digital economy ecosystem said Karnataka’s long-standing strengths in talent, research an...

Tata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...

Biocon's Executive Chairperson, Kiran Mazumdar-Shaw, outlined a five-year leadership transition with her niece, Claire Mazumdar, as success...

Biocon's fourth-quarter net profit saw a significant drop of 63 percent year-on-year. This decline was attributed to exceptional charges im...

Biocon Ltd reported a 56.8% drop in Q4 net profit to Rs 198.6 crore, impacted by an Rs 80.4 crore exceptional item. Despite this, consolida...

Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by...

Markets closed lower amid global headwinds and geopolitical worries. Several companies like Paytm, Bajaj Auto, and L&T are in focus due to ...

Biocon's founder Kiran Mazumdar-Shaw has made a groundbreaking announcement, pledging her niece Claire Mazumdar as her heir apparent. The t...

Biocon's chairperson, Kiran Mazumdar-Shaw, has named her niece, Claire Mazumdar, as her successor, sparking a more than 1% jump in the comp...

Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...

US company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...

Biocon announced a leadership change. Siddharth Mittal will step down as Managing Director and Chief Executive Officer on March 31. He will...

The transaction with US-based Viatris required regulatory approvals from the Reserve Bank of India, Competition Commission of India and the...

The former VC of Biocon passed away on Monday at the age of 73.

The deal with Serum Institute Life Sciences values Biocon Biologics at about $4.9 billion and will solely focus on COVID-19 vaccines in the...

A Biocon veteran, Shreehas Tambe joined the company in 1997 and has more than 20 years of leadership experience in operational and strategi...